Programming of influenza vaccine broadness and persistence by mucoadhesive polymer-based adjuvant systems

Journal of Immunology

Volumn 195, Issue 5, 2015, Pages 2472-2482

  Noh, Hyun Jong ^a   Chowdhury, Mohammed Y E ^b,c   Cho, Seonghun ^b   Kim, Jae Hoon ^b   Park, Hye Sun ^d   Kim, Chul Joong ^b   Poo, Haryoung ^e   Sung, Moon Hee ^f   Lee, Jong Soo ^b   Lim, Yong Taik ^a  

^a Sungkyunkwan University   (South Korea)

^b Chungnam National University   (South Korea)

^c Chittagong Government Veterinary College   (Bangladesh)

^d Korea Basic Science Institute (KBSI)   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^f Kookmin University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MATRIX PROTEIN 2 HEMAGGLUTININ 2 FUSION PROTEIN; PHOSPHORYL LIPID A; POLYGLUTAMIC ACID; QS 21; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; POLY(GAMMA-GLUTAMIC ACID); POLYMER;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROGRAM; HUMORAL IMMUNITY; HYDROGEN BOND; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A (H5N2); INFLUENZA A (H7N3); INFLUENZA A (H9N2); INFLUENZA VACCINATION; MOUSE; MUCOADHESION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CROSS PROTECTION; HOST PATHOGEN INTERACTION; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H5N2); INFLUENZA A VIRUS (H7N3); INFLUENZA A VIRUS (H9N2); MUCOSAL IMMUNITY; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CROSS PROTECTION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HOST-PATHOGEN INTERACTIONS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA A VIRUS, H7N3 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POLYGLUTAMIC ACID; POLYMERS; VIRAL MATRIX PROTEINS;

EID: 84940112104     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500492     Document Type: Article

References (58)

1. Subbarao, K., and T. Joseph. 2007. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 7: 267-278.
2. Neumann, G., T. Noda, and Y. Kawaoka. 2009. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
3. Stephenson, I., and K. Nicholson. 2001. Influenza: vaccination and treatment. Eur. Respir. J. 17: 1282-1293.
4. Lambert, L. C., and A. S. Fauci. 2010. Influenza vaccines for the future. N. Engl. J. Med. 363: 2036-2044.
5. Gerdil, C. 2003. The annual production cycle for influenza vaccine. Vaccine 21: 1776-1779.
6. Smith, D. J., A. S. Lapedes, J. C. de Jong, T. M. Bestebroer, G. F. Rimmelzwaan, A. D. M. E. Osterhaus, and R. A. M. Fouchier. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.
7. Shim, B. S., Y. K. Choi, C. H. Yun, E. G. Lee, Y. S. Jeon, S. M. Park, I. S. Cheon, D. H. Joo, C. H. Cho, M. S. Song, et al. 2011. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 6: e27953.
8. Du, L., Y. Zhou, and S. Jiang. 2010. Research and development of universal influenza vaccines. Microbes Infect. 12: 280-286.
9. Prabhu, N., M. Prabakaran, H. T. Ho, S. Velumani, J. Qiang, M. Goutama, and J. Kwang. 2009. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83: 2553-2562.
10. O'Hagan, D. T., and N. M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2: 727-735.
11. Reed, S. G., M. T. Orr, and C. B. Fox. 2013. Key roles of adjuvants in modern vaccines. Nat. Med. 19: 1597-1608.
12. Kang, S. M., J. M. Song, and R. W. Compans. 2011. Novel vaccines against influenza viruses. Virus Res. 162: 31-38.
13. Vogel, F. R., C. Caillet, I. C. Kusters, and J. Haensler. 2009. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines 8: 483-492.
14. Rhee, J. H., S. E. Lee, and S. Y. Kim. 2012. Mucosal vaccine adjuvants update.Clin. Exp. Vaccine Res. 1: 50-63.
15. Ellebedy, A. H., M. F. Ducatez, S. Duan, E. Stigger-Rosser, A. M. Rubrum, E. A. Govorkova, R. G.Webster, and R. J. Webby. 2011. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine 29: 3335-3339.
16. Kiyono, H., and S. Fukuyama. 2004. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4: 699-710.
17. Rose, M. A., S. Zielen, and U. Baumann. 2012. Mucosal immunity and nasal influenza vaccination. Expert Rev. Vaccines 11: 595-607.
18. Wegmann, F., K. H. Gartlan, A. M. Harandi, S. A. Brinckmann, M. Coccia, W. R. Hillson, W. L. Kok, S. Cole, L. P. Ho, T. Lambe, et al. 2012. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat. Biotechnol. 30: 883-888.
19. Lycke, N. 2012. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12: 592-605.
20. Buescher, J. M., and A. Margaritis. 2007. Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries. Crit. Rev. Biotechnol. 27: 1-19.
21. Kim, T. W., T. Y. Lee, H. C. Bae, J. H. Hahm, Y. H. Kim, C. Park, T. H. Kang, C. J. Kim, M. H. Sung, and H. Poo. 2007. Oral administration of high molecular mass poly-g-glutamate induces NK cell-mediated antitumor immunity. J. Immunol. 179: 775-780.
22. Mohan, T., P. Verma, and D. N. Rao. 2013. Novel adjuvants and delivery vehicles for vaccines development: A road ahead. Indian J. Med. Res. 138: 779.
23. Brito, L. A., P. Malyala, and D. T. O'Hagan. 2013. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin. Immunol. 25: 130-145.
24. Pfaar, O., D. Cazan, L. Klimek, D. Larenas-Linnemann, and M. A. Calderon. 2012. Adjuvants for immunotherapy. Curr. Opin. Allergy Clin. Immunol. 12: 648-657.
25. Vandepapelière, P., Y. Horsmans, P. Moris, M. Van Mechelen, M. Janssens, M. Koutsoukos, P. Van Belle, F. Clement, E. Hanon, M. Wettendorff, et al. 2008. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26: 1375-1386.
26. Dendouga, N., M. Fochesato, L. Lockman, S. Mossman, and S. L. Giannini. 2012. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 30: 3126-3135.
27. Ragupathi, G., J. R. Gardner, P. O. Livingston, and D. Y. Gin. 2011. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev. Vaccines 10: 463-470.
28. Liu, W., P. Zou, and Y. H. Chen. 2004. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol. Lett. 93: 131-136.
29. Song, J. M., J. Hossain, D. G. Yoo, A. S. Lipatov, C. T. Davis, F. S. Quan, L. M. Chen, R. J. Hogan, R. O. Donis, R. W. Compans, and S. M. Kang. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405: 165-175.
30. Lee, J. S., M. Y. Chowdhury, H. J. Moon, Y. K. Choi, M. R. Talactac, J. H. Kim, M. E. Park, H. Y. Son, K. S. Shin, and C. J. Kim. 2013. The highly conserved HA2 protein of the influenza a virus induces a cross protective immune response. J. Virol. Methods 194: 280-288.
31. Chowdhury, M.Y. E., S. K. Seo, H. J. Moon, M. R. Talactac, J. H. Kim, M. E. Park, H. Y. Son, J. S. Lee, and C. J. Kim. 2014. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice. Virol. J. 11: 21.
32. Price, G. E., M. R. Soboleski, C. Y. Lo, J. A. Misplon, M. R. Quirion,K. V. Houser, M. B. Pearce, C. Pappas, T. M. Tumpey, and S. L. Epstein. 2010. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5: e13162.
33. Tompkins, S. M., C. Y. Lo, T. M. Tumpey, and S. L. Epstein. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101: 8682-8686.
34. Sui, Z., Q. Chen, F. Fang, M. Zheng, and Z. Chen. 2010. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28: 7690-7698.
35. Geidobler, R., and G. Winter. 2013. Controlled ice nucleation in the field of freeze-drying: fundamentals and technology review. Eur. J. Pharm. Biopharm.85: 214-222.
36. Shih, I. L., and Y. T. Van. 2001. The production of poly-(γ-glutamic acid) from microorganisms and its various applications. Bioresour. Technol. 79: 207-225.
37. Bhushan, K. R., P. Misra, F. Liu, S. Mathur, R. E. Lenkinski, and J. V. Frangioni. 2008. Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe. J. Am. Chem. Soc. 130: 17648-17649.
38. Salamat-Miller, N., M. Chittchang, and T. P. Johnston. 2005. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 57: 1666-1691.
39. Bagan, J., C. Paderni, N. Termine, G. Campisi, L. Lo Russo, D. Compilato, and O. Di Fede. 2012. Mucoadhesive polymers for oral transmucosal drug delivery: a review. Curr. Pharm. Des. 18: 5497-5514.
40. Washington, N., R. J. Steele, S. J. Jackson, D. Bush, J. Mason, D. A. Gill, K. Pitt, and D. A. Rawlins. 2000. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int. J. Pharm. 198: 139-146.
41. Seo, S. H., and R. G. Webster. 2001. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J. Virol. 75: 2516-2525.
42. Huleatt, J. W., V. Nakaar, P. Desai, Y. Huang, D. Hewitt, A. Jacobs, J. Tang, W. McDonald, L. Song, R. K. Evans, et al. 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
43. Neirynck, S., T. Deroo, X. Saelens, P. Vanlandschoot, W. M. Jou, and W. Fiers. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5: 1157-1163.
44. Eliasson, D. G., K. E. Bakkouri, K. Schön, A. Ramne, E. Festjens, B. Löwenadler, W. Fiers, X. Saelens, and N. Lycke. 2008. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
45. Jegerlehner, A., N. Schmitz, T. Storni, and M. F. Bachmann. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172: 5598-5605.
46. Staneková, Z., I. Adkins, M. Kosová, J. Janulíková, P. Šebo, and E. Varečková. 2013. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin. Antiviral Res. 97: 24-35.
47. Bommakanti, G., M. P. Citron, R. W. Hepler, C. Callahan, G. J. Heidecker, T. A. Najar, X. Lu, J. G. Joyce, J. W. Shiver, D. R. Casimiro, et al. 2010. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. USA. 107: 13701-13706.
48. Bessa, J., N. Schmitz, H. J. Hinton, K. Schwarz, A. Jegerlehner, and M. F. Bachmann. 2008. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 38: 114-126.
49. Fan, J., X. Liang, M. S. Horton, H. C. Perry, M. P. Citron, G. J. Heidecker, T. M. Fu, J. Joyce, C. T. Przysiecki, P. M. Keller, et al. 2004. Preclinical study of influenza virus A M2 peptide conjugates vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
50. De Filette, M., A. Ramne, A. Birkett, N. Lycke, B. Löwenadler, J. W. Min, X. Saelens, and W. Fiers. 2006. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-551.
51. Okuda, K., A. Ihata, S. Watabe, E. Okada, T. Yamakawa, K. Hamajima, J. Yang, N. Ishii, M. Nakazawa, K. Okuda, et al. 2001. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19: 3681-3691.
52. Yonezawa, H., K. Ishihara, and K. Okuda. 2001. Arg-gingipain a DNA vaccine induces protective immunity against infection by Porphyromonas gingivalis in a murine model. Infect. Immun. 69: 2858-2864.
53. Price, G. E., M. R. Soboleski, C. Y. Lo, J. A. Misplon, C. Pappas, K. V. Houser, T. M. Tumpey, and S. L. Epstein. 2009. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512-6521.
54. Cao, W., Y. Chen, S. Alkan, A. Subramaniam, F. Long, H. Liu, R. Diao, T. Delohery, J. McCormick, R. Chen, et al. 2005. Human T helper (Th) cell lineage commitment is not directly linked to the secretion of IFN-γ or IL-4: Characterization of Th cells isolated by FACS based on IFN-γ and IL-4 secretion. Eur. J. Immunol. 35: 2709-2717.
55. Quan, F. S., A. Vunnava, R. W. Compans, and S. M. Kang. 2010. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 5: e9161.
56. Wu, F., X. Y. Yuan, J. Li, and Y. H. Chen. 2009. The co-administration of CpGODN influenced protective activity of influenza M2e vaccine. Vaccine 27: 4320-4324.
57. Mitragotri, S. 2006. Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov. 5: 543-548.
58. Köping-Höggård, M., A. Sánchez, and M. J. Alonso. 2005. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev. Vaccines 4: 185-196.